Agenus R&D update & Second Quarter Earnings Report

On July 29, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, reported it will provide an update on programs and plans and release its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020 (Press release, Agenus, JUL 29, 2020, View Source [SID1234562506]). Agenus executives and thought leaders will host a video conference call and webcast at 8:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Topics to be discussed:

Registration plans and strategy for balstilimab +/- zalifrelimab
Agenus & Betta Pharmaceuticals partnership progress for China
Clinical status/next steps for AGEN1181 (NextGen CTLA-4) +/- balstilimab (anti-PD-1)
Allogeneic iNKT cells potential breakthrough for COVID-19 and cancer based on efficacy and cost
Cell therapy and antibody combinations preclinically show curative potential
AGEN1223 & AGEN2373 clinical update and plans for bali +/- zali combos
Myeloid immune response modifiers (TIGIT bispecific & other novel targets)
Live Call: Dial 1-844-492-3727 (U.S.) or 1-412-317-5118 (International)

Webcast: The call will be accessible from the Company’s website at View Source or via View Source A replay will be available approximately two hours after the call and will remain available until November 7, 2020.

Pancreatic Cancer Action Network and GeneCentric Therapeutics Launch Partnership in Pancreatic Cancer Research

On July 29, 2020 The Pancreatic Cancer Action Network (PanCAN) and GeneCentric Therapeutics, Inc. reported that they have entered into a collaborative research partnership for the advancement of RNA-based molecular signatures for pancreatic cancer disease progression and drug response (Press release, GeneCentric Therapeutics, JUL 29, 2020, View Source [SID1234562523]). The collaboration will combine GeneCentric’s single patient RNA-based report, including its Pancreatic Cancer Subtype Profiler (PurIST) for subtyping pancreatic ductal adenocarcinoma tumors (PDAC), with PanCAN’s extensive collection of patient molecular and outcomes data generated through its scientific and clinical programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"GeneCentric is advancing promising molecular signatures of disease progression and drug response in pancreatic cancer based on tumor subtyping through next generation RNA sequencing of the tumor and tumor/immune microenvironment, and immunogenomics," said Dr. Lynn Matrisian, Chief Science Officer of PanCAN. "The collaboration, which will involve profiling and data analyses from our Know Your Tumor program and Precision PromiseSM adaptive clinical trial, is designed to advance our goals of improving treatment responses and survival of PDAC patients, accelerating the development of novel therapies and defining potential curative strategies for people diagnosed with this devastating disease."

"PanCAN, with its leading-edge, innovative research programs to accelerate new therapies to the clinic and dramatically improve treatment options for pancreatic cancer patients, is an ideal partner for GeneCentric," said Dr. Mike Milburn, President and CEO of GeneCentric. "We are honored to work with the PanCAN team and their renowned collaborators to advance and apply novel molecular signatures to support landmark initiatives such as the Precision Promise study as well as other pivotal research in the pursuit of cures for patients."

The collaboration will involve two research projects and is focused on GeneCentric’s single patient molecular report, including two PurIST defined PDAC subtypes, Basal (gemcitabine/nab-paclitaxel responsive) and Classical (FOLFRINOX responsive). One study, aimed at the molecular characterization of potential treatment response, will be a retrospective analysis of patient data from the Know Your Tumor Program at diagnosis and treatment outcome. The second initiative is in conjunction with PanCAN’s Precision PromiseSM clinical trial to assess molecular signatures of patients at enrollment and association with treatment responses. The three-year study will enable application of the range of GeneCentric’s current PDAC as well as pan-cancer tumor and immunogenomic signatures of treatment response, as well as exploration of novel PDAC-related signatures.

Novartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation

On July 29, 2020 Novartis reported the European Commission (EC) reportedhas approved Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (Press release, Novartis, JUL 29, 2020, View Source [SID1234562481]). Piqray is the first and only treatment specifically approved for people with advanced breast cancer whose tumors harbor a PIK3CA mutation, which stimulates tumor growth and is associated with poor response to therapy13.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Piqray is an important new therapy for HR+/HER2- advanced breast cancer patients whose tumors have a PIK3CA mutation, and we look forward to making it available in countries across Europe," said Kees Roks, Head Region Europe, Novartis Oncology. "Knowledge of PIK3CA status can better equip doctors as they develop a personalized upfront treatment plan for patients. Piqray offers new hope for advanced breast cancer patients with a PIK3CA mutation, who typically face a worse overall prognosis."

This approval follows a positive opinion granted in May by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based on the Phase III SOLAR-1 trial showing that Piqray nearly doubled median progression-free survival (PFS) compared to fulvestrant alone1,2. Overall response rate, an indicator of the proportion of patients who experience at least a 30% reduction in overall tumor size (in patients with measurable disease), was more than doubled when Piqray was added to fulvestrant compared to fulvestrant alone1,2. Read more about the positive CHMP opinion and the SOLAR-1 clinical trial results here.

Patients with HR+/HER2- advanced breast cancer should be selected for treatment with Piqray based on the presence of a PIK3CA mutation in tumor or plasma specimens, using a validated test. If a mutation is not detected in a plasma specimen, tumor tissue should be tested if available.

About Piqray (alpelisib)
Piqray is a kinase inhibitor developed for use in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+/HER2-, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after endocrine-based regimen. Piqray is approved in 48 countries, including the US and European member states.

Important Safety Information from the PIQRAY EU SmPC
The most common ADRs and the most common grade 3 / 4 ADRs (reported at a frequency >20% and ≥2%, respectively) were plasma glucose increased, creatinine increased, gamma-glutamyltransferase increased, rash, lymphocyte count decreased, nausea, alanine aminotransferase increased, anaemia, fatigue, lipase increased, decreased appetite*, stomatitis, vomiting*, weight decreased, hypocalcaemia, plasma glucose decreased*, activated partial thromboplastin time prolonged*, alopecia**, diarrhoea, hypokalaemia, hypertension, nausea, creatinine increased, and mucosal inflammation (*<2% grade 3/4 ADRs reported, ** no grade 3/4 ADRs reported).

Piqray can cause serious side effects such as severe hypersensitivity, severe cutaneous reactions, hyperglycaemia, pneumonitis, diarrhoea, and osteonecrosis of the jaw.

The following should be taken into consideration prior to or during treatment with Piqray:

Piqray should be permanently discontinued in patients with serious hypersensitivity reactions.

Piqray should not be initiated in patients with a history of severe cutaneous reactions, should be interrupted if signs or symptoms of severe cutaneous reactions are present, and permanently discontinued if a severe cutaneous reaction is confirmed.

Fasting glucose and HbA1c levels should be monitored frequently in the first 4 weeks of treatment, and patients should be advised of the signs and symptoms of hyperglycaemia.

In case of new or worsening respiratory symptoms, the patient should be evaluated for pneumonitis.

Patients should be advised to notify their physician if diarrhoea occurs.

Caution should be exercised when Piqray and bisphosphonates or denosumab are used together or sequentially. Piqray should not be initiated in patients with ongoing osteonecrosis of the jaw.

The efficacy and safety of Piqray has not been studied in patients with symptomatic visceral disease.

Animal studies suggest that Piqray may cause fetal harm in pregnant women. Therefore, as a precaution, women of childbearing potential should use effective contraception while receiving Piqray during treatment and at least 1 week after stopping treatment. Women should not breast feed for at least 1 week after the last dose of Piqray. Piqray may affect fertility in males and females.

Perrigo Announces Quarterly Dividend

On July 29, 2020 Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, reported that its Board of Directors declared a quarterly dividend of $0.225 per share, payable on September 15, 2020 to shareholders of record on August 28, 2020 (Press release, Perrigo Company, JUL 29, 2020, View Source [SID1234562507]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020

On July 29, 2020 Exelixis, Inc. (Nasdaq: EXEL) reported that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 after the markets close. At 5:30 p.m. EDT / 2:30 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update (Press release, Exelixis, JUL 29, 2020, View Source [SID1234562524]). Access to the event is available via the Internet from the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 6548897 to join by phone.

A telephone replay will be available until 8:00 p.m. EDT on August 8, 2020. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 6548897. A webcast replay will also be archived on www.exelixis.com for one year.